The thyroid Cancer Genome Atlas reported that classification of adult PTC into molecularly defined groups, RAS-like and BRAF-like, more accurately reflects cellular signaling, cellular differentiation, and clinical behavior when compared with histology alone.1 Our data suggest that separating pediatric PTC with BRAF p.V600E mutations from PTC with RET/NTRK fusions more closely aligns with clinicopathologic features with BRAF-positive PTC less common with decreased age and RET/NTRK fusion–positive PTC more commonly associated with lateral neck (N1b) and distant (M1, pulmonary) metastasis. The gene discussed is BRAF; the disease is thyroid cancer.